{"retracted":true,"timestamp":1341273600000,"update":{"timestamp":null,"doi":null,"pmid":22893217,"type":"retraction"},"doi":"10.1124/jpet.112.193946","journal":"The Journal of pharmacology and experimental therapeutics","publisher":null,"title":"A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice."}
